# CLINICAL GUIDANCE: EXPOSURE TO PER- AND POLYFLUOROALKYL SUBSTANCES (PFAS)

The National Academies of Science, Engineering, and Medicine (NASEM) recently published a set of clinical guidelines for health care providers to advise patients on exposure reduction and set parameters for testing.

#### **Environmental Exposure Assessment**

# Prior to testing, determine the primary sources of exposure:

- Occupation
- Industrial contamination
- Consumption of fish and/or game from contaminated areas



Look out for consumption advisories and contact occupational health and safety professionals to aid in this process

#### **Patient Recommendations**

For patients at an increased risk of exposure to PFAS in drinking water, recommend using filters in their home.

PFAS exposure through breastmilk is a

PFAS exposure through breastmilk is a possible risk. However, advise pregnant/nursing patients that it is unknown if this outweighs the known benefits

#### Prioritize reccomending testing for patients in:

- Specific occupations (ie: military & firefighters)
- Known contaminated water sources
- Close proximity to industrial exposure such as, facilities that use fluorochemicals, airports, military bases, wastewater treatment plants, sewage sludge applications, landfills or incinerators.

### **Testing Guidelines**

#### If testing is recommended:

- Inform patients of the risks
- Test for the sum of total PFAS (PFOA, PFOS, MeFOSAA, PFHxS, PFDA, PFUnDA, and PFNA) in serum or plasma
- Care should be taken with the interpretation of capillary blood samples.

## **Interpreting results**

<2 ng/ML

Adverse effects not expected due to PFAS exposure

2-20 ng/ML

Potential for adverse effects, increases for susceptible populations >20 ng/ML

Increased risk of adverse effects



#### **Clinical Follow Up**

The NASEM report contains detailed guidelines for follow up if the patient tests results are within the range of concern. Scan the QR code or visit https://nap.nationalacademies.org/catalog/26156/guidance-on-pfas-exposure-

testing-and-clinical-follow-up to learn more